Press release
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of
About this update from Geron Corporation
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023. Ms. Robertson's appointment follows the retirement of Olivia Bloom, Geron's incumbent CFO, also effective September 25, 2023. Ms. Bloom's retirement brings to a close a remarkable career of nearly 30 years on Geron’s finance team, including serving the last twelve years as CFO.\n\n\n“On behalf of the Board and our entire team, I would first like to express our deep appreciation and admiration for the countless contributions Olivia has made during her extraordinary tenure at Geron, from the Company’s early days as a discovery-focused organization through today when we are preparing for the potential commercialization of imetelstat in lower risk myelodysplastic syndromes. Olivia’s strategic vision, financial prowess and inspiring dedication have been foundational in making Geron what we are today,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer. “In the same breath, I am also thrilled to welcome Michelle Robertson to the Geron executive management team at this important moment in our history. Michelle's deep command of financial operations, her experience with managing the financial and organizational needs of a biotechnology company preparing to potentially launch its first commercial product, her prior experience with investors, analysts and investment bankers, and her hands-on experiences with commercial launches in the past will all be extremely valuable to our organization at this point in our corporate evolution.”\n\n\n“It has been the privilege of my career to watch telomerase inhibition advance from a scientific hypothesis to a novel oncology approach that could potentially transform the treatment of hematologic malignancies,” said Ms. Bloom. “I have confidence in Michelle and the rest of the Geron team to deliver on Geron’s future milestones as the company enters a new era of potential commercialization.” Ms. Bloom will serve as a consultant to the company through March 1, 2024 to support a smooth transition of her role to Ms. Robertson.\n\n\nMs. Robertson brings to Geron over 30 years of financial and commercial opera...